Group 1 - The demand for antithrombotic drugs is expanding due to the aging population and rising prevalence of cardiovascular diseases, with the global market size reaching $52.9 billion in 2023 and expected to exceed $110 billion by 2033 [2] - Anticoagulants are the core category within this market, showing steady growth, particularly in China, which provides a broad market foundation for the development and commercialization of new anticoagulants [2] - The upgrade window for anticoagulants has arrived, with the next generation of drugs poised for development as traditional anticoagulants struggle to balance efficacy and bleeding risks [2] Group 2 - FXI is identified as a key target for the next generation of anticoagulants due to its unique advantages of "precise anticoagulation and low bleeding risk," with multiple FXI/FXIa inhibitors currently in registration clinical stages globally [3] - Bayer's Asundexian and BMS/Johnson & Johnson's Milvexian are among the small molecule FXIa inhibitors undergoing clinical trials, with varying degrees of success in different indications [4] - In the realm of monoclonal antibodies, Novartis' Abelacimab has received FDA fast track designation for stroke prevention in atrial fibrillation and cancer-related thrombosis, while Regeneron is advancing two FXI monoclonal antibodies into Phase III trials [4] Group 3 - Recommended companies include Heng Rui Medicine (01276), with related companies being Reblozyl Bio-B (06938) and Jingyin Pharmaceutical [5]

Group 1 - Dongyangguang plans to acquire control of Dongshu Yihua, which was established for the acquisition of Qinhuai Data [1] - Kaipu Cloud terminates the acquisition of 100% equity in Nanning Taike [1] - YN Energy Holdings only holds a stake in Xiantian Computing and does not consolidate financial statements; its main business remains thermal power generation [1] - Jiaze New Energy's green chemical business is still in the early stages and has not yet been commercialized [1] Group 2 - Tongwei Co. plans to issue shares and cash to acquire 100% equity in Qinghai Lihua Qingneng and has suspended trading to plan the transaction [2] - Hengrui Medicine's SHR-1918 injection application has been accepted by the National Medical Products Administration and included in priority review [2] - ST Renfu plans to raise no more than 3.5 billion yuan through a private placement to its controlling shareholder [2] - Changxin Bochuang intends to acquire 93.81% equity in Shanghai Honghui Guanglian Communication Technology Co., expanding into the upstream of the optical communication industry chain [2] - Bohai Leasing's subsidiary sells 24 aircraft leasing assets with a market price of approximately 1.589 billion USD [2] - Shenlian Bio plans to acquire control of Shizhi Yuan for 237 million yuan and develop innovative drug business [2] - Sainuo Medical's subsidiary product Ghunter intracranial thrombectomy stent has obtained EU CE MDR certification [2] - Dazhu Laser plans to invest 150 million USD to establish an overseas operation center in Southeast Asia [2] - ST Songfa's subsidiary Henglizhaobing has signed contracts for the construction of two Capesize bulk carriers [2] - Shaaneng Co.'s wholly-owned subsidiary has signed a cooperation agreement for land and power resources for an independent energy storage project with Yuancan Company [2] - Guangxi Media's film "Fast Life 3" has a cumulative box office of 2.926 billion yuan, generating revenue of 43-53 million yuan; "Silent Insect" has a box office of 867 million yuan, generating revenue of 5.2-6.6 million yuan [2] - Xingfu Blue Sea's revenue from two films "Fast Life 3" and "Bears: Year of the Bear" totals approximately 790,000-1.02 million yuan [2] - Huazhi Digital Media's film "Silent Insect" has a cumulative box office exceeding 900 million yuan, accounting for over 50% of the recent year's revenue [2] - Xiangyuan Cultural Tourism received 1.1428 million visitors during the 2026 Spring Festival, achieving revenue of 70.9237 million yuan [2] - Sanan Optoelectronics plans to dispose of equipment that does not meet demand, with a book value of 447 million yuan [2] Group 3 - Sangfor Technologies expects a net profit growth of 317.09% in 2025 [3] - Yongxi Electronics anticipates a net profit of 82.24 million yuan in 2025, a year-on-year increase of 23.99% [3] - Zhongke Shuguang forecasts a net profit of 2.113 billion yuan in 2025, a year-on-year growth of 11% [3]

Core Viewpoint - Jiangsu Hengrui Medicine Co., Ltd. has received a notice from the National Medical Products Administration regarding the acceptance of its innovative drug SHR-1918 injection for marketing approval, which has been included in the priority review process [1] Drug Basic Information - Drug Name: SHR-1918 Injection - Dosage Form: Injection - Acceptance Number: CXSS2600019 - Application Stage: Marketing - Applicant: Beijing Shengdi Pharmaceutical Co., Ltd. - Indication: Treatment of adult and adolescent patients aged 12 years and older with homozygous familial hypercholesterolemia (HoFH) [1] Clinical Trial Information - The marketing application is based on two clinical trials for HoFH patients: SHR-1918-202 and SHR-1918-301, led by Professor Peng Daoquan from Central South University [2] - SHR-1918-202 is a Phase II multicenter, single-arm trial in adult HoFH patients, showing an average reduction of 59.1% in serum low-density lipoprotein cholesterol (LDL-C) with a significant absolute reduction of 6.6 mmol/L [2] - SHR-1918-301 is a Phase III randomized, double-blind, placebo-controlled trial in patients aged ≥12 years, confirming similar lipid-lowering efficacy and good safety profile [2] Additional Drug Information - Homozygous familial hypercholesterolemia is a rare and life-threatening autosomal dominant genetic disorder characterized by significantly elevated serum LDL-C levels, often exceeding 13 mmol/L, leading to early-onset atherosclerotic cardiovascular disease (ASCVD) [3] - SHR-1918 injection is a monoclonal antibody targeting angiopoietin-like protein 3 (ANGPTL3), aimed at lowering triglycerides (TG) and LDL-C levels [3] - The global sales forecast for a similar drug, EVKEEZA (evinacumab-dgnb) by Regeneron, is approximately $216 million by 2025 [3] - Cumulative R&D investment for SHR-1918 injection is approximately 24.22 million yuan (unaudited) [3]

Core Viewpoint - Heng Rui Medicine's subsidiary, Beijing Shengdi Pharmaceutical Co., Ltd., has received a notice from the National Medical Products Administration regarding the acceptance of its drug listing application for the innovative drug SHR-1918 injection, which has been included in the priority review process [1] Group 1 - The SHR-1918 injection is a monoclonal antibody targeting angiopoietin-like protein 3 (ANGPTL3), developed independently by Heng Rui Medicine [1] - The mechanism of SHR-1918 involves inhibiting the activity of ANGPTL3 to lower serum triglycerides (TG) and LDL-C levels [1] - The proposed indication for SHR-1918 is for the treatment of adult and adolescent patients aged 12 years and older with homozygous familial hypercholesterolemia [1]

Core Viewpoint - Heng Rui Medicine's subsidiary, Beijing Shengdi Pharmaceutical Co., Ltd., has received a "Notice of Acceptance" from the National Medical Products Administration for its innovative drug SHR-1918 injection, which has been included in the priority review process [1] Group 1: Product Development - SHR-1918 injection is a monoclonal antibody targeting angiopoietin-like protein 3 (ANGPTL3), aimed at reducing serum triglycerides (TG) and LDL-C levels [1] - The total R&D investment for the SHR-1918 injection project has reached approximately 242.2 million yuan (unaudited) [1] Group 2: Market Context - The only other drug targeting the same pathway is Regeneron's EVKEEZA® (evinacumab-dgnb), which has been approved and is projected to generate global sales of approximately $216 million by 2025 [1]

Group 1 - The core point of the article is that Heng Rui Medicine (01276.HK) announced that its subsidiary, Beijing Shengdi Pharmaceutical Co., Ltd., has received a "Notice of Acceptance" from the National Medical Products Administration for its innovative drug SHR-1918 injection, which has been accepted for review and included in the priority review process [1] Group 2 - The drug SHR-1918 is classified as a Class 1 innovative drug, indicating its potential significance in the pharmaceutical market [1] - The inclusion in the priority review process suggests that the regulatory body recognizes the drug's importance and aims to expedite its approval [1]

Core Viewpoint - Heng Rui Medicine's subsidiary, Beijing Shengdi Pharmaceutical Co., Ltd., has received a notice of acceptance from the National Medical Products Administration for the marketing authorization application of its innovative drug SHR-1918 injection, which has been included in the priority review process [1] Group 1 - The application for market approval is based on two clinical trials targeting patients with Homozygous Familial Hypercholesterolemia (HoFH): SHR-1918-202 and SHR-1918-301, led by Professor Peng Daoquan from Central South University Xiangya Second Hospital [2] - The SHR-1918-202 study is a Phase II multicenter, single-arm trial conducted in adult HoFH patients, with results published in the Journal of the American College of Cardiology, showing an average reduction of 59.1% in serum low-density lipoprotein cholesterol (LDL-C) with a significant absolute reduction of 6.6 mmol/L, indicating substantial and sustained LDL-C level reduction with good safety and tolerability [2] - The SHR-1918-301 study is a randomized, double-blind, placebo-controlled Phase III clinical trial involving HoFH patients aged 12 and older, conducted across 16 clinical research centers nationwide, with lipid-lowering efficacy characteristics highly consistent with the SHR-1918-202 study results and good safety [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 孫飄揚先生 中國上海 2026年2月24日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，江苏恒瑞医药股份有限公司（以下简称"公司"）子公司北京盛迪医 药有限公司收到国家药品监督管理局（以下简称"国家药监局"）下发的《受理 通知书》，公司 1 类 ...

Core Viewpoint - Heng Rui Medicine emphasizes its commitment to a technology innovation strategy, expanding its product pipeline to address unmet clinical needs in chronic disease management while continuing to deepen its focus on oncology [1] Group 1: R&D Strategy - The company is broadening its research and development efforts beyond oncology to include metabolic and cardiovascular diseases, immune and respiratory diseases, and neuroscience [1] - Several innovative products have already been approved for market, targeting conditions such as type 2 diabetes, atopic dermatitis, psoriasis, rheumatoid arthritis, ankylosing spondylitis, and hypercholesterolemia [1] Group 2: Product Pipeline - The company has a diverse pipeline with dozens of new drugs currently in clinical development [1]

药品名称：SHR-1918 注射液 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2026-026 江苏恒瑞医药股份有限公司 关于药品上市许可申请获受理并纳入优先审评程序 的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，江苏恒瑞医药股份有限公司（以下简称"公司"）子公司北京盛迪医 药有限公司收到国家药品监督管理局（以下简称"国家药监局"）下发的《受理 通知书》，公司 1 类创新药 SHR-1918 注射液的药品上市许可申请获受理，且已 被纳入优先审评程序。现将相关情况公告如下： 一、药品的基本情况 剂型：注射剂 受理号：CXSS2600019 申请人：北京盛迪医药有限公司 申报阶段：上市 拟定适应症（或功能主治）：用于治疗成人和 12 岁及以上的未成年人纯合 子家族性高胆固醇血症（HoFH）患者。 二、药品的临床试验情况 此次申报上市是基于两项针对 HoFH 患者的临床试验：SHR-1918-202 研究和 SHR-1918-301 研究，均由中南大学湘雅二医院彭道泉教授牵头开展，全面评估 了药 ...